DR REDDYS LABORATORIES Business Summary

Dr. Reddy's Laboratories Ltd. (RDY) operates a high-volume pharmaceutical business model primarily driven by the transactional sale of generic formulations, active pharmaceutical ingredients (APIs), and biosimilars. Revenue is generated through four primary segments: Global Generics, which covers branded and unbranded formulations across North America, Europe, India, and Emerging Markets; Pharmaceutical Services and Active Ingredients (PSAI), focusing on contract manufacturing and research; Innovative Medicines; and Consumer Health. As of February 2026, the company derives approximately 34% of its revenue from North America and 18% from India, with a strategic focus on complex generics and a robust biosimilar pipeline including semaglutide and rituximab. Dr. Reddy's competes directly with global and domestic leaders such as Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Aurobindo Pharma, and Cipla, maintaining a premier position as one of the world's top 10 generic manufacturers and the second-largest pharmaceutical company in India by revenue. Founded in 1984 by the late Dr. Kallam Anji Reddy, the company is currently led by a seasoned executive team including Chairman Kallam Satish Reddy and Co-Chairman & Managing Director G.V. Prasad, who was recently re-appointed for a five-year term beginning January 30, 2026. Erez Israeli, formerly a senior executive at Teva Pharmaceuticals, serves as the Chief Executive Officer, while M.V. Narasimham holds the role of Chief Financial Officer. The leadership team is supported by key business heads such as Milan Kalawadia (CEO, North America Generics) and Deepak Sapra (CEO, API & Services). The company maintains a high-pedigree board with independent directors including former Axis Bank CEO Shikha Sharma and Sanjiv Mehta. Notable institutional investors include global asset management giants BlackRock, Vanguard, and Morgan Stanley, reflecting the company's significant presence in international capital markets.